- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
What Post-Void MRIs May Reveal About Midline Radiotracer Activity on PSMA PET/CT
Patients with localized high-risk prostate cancer and midline radiotracer activity in the prostate had over double the incidence of urethral hyperintensity on T2W MRI, according to research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).
Post-void magnetic resonance imaging (MRI) may provide enhanced clarity as to the nature of midline prostate-specific membrane antigen (PSMA) radiotracer uptake on positron emission tomography (PET) scans for patients with localized, high-risk prostate cancer.
In a study presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU) in San Francisco, researchers reviewed PSMA PET and T2W MRI imaging for 84 patients with localized, high-risk prostate cancer. Sixty-eight patients had no midline prostate activity on PSMA PET and 16 patients who had had midline radiotracer activity with 18F-DCFPyL, according to the study.
The study authors found that 75 percent of patients with prostate midline tracer uptake on PSMA PET had urethral hyperintensity on post-void MRI exams in comparison to 31 percent of patients with no midline tracer activity on PSMA PET imaging.
For patients with urethral hyperintensity on post-void MRI exams, researchers noted significantly increased mean axial (7.25 mm vs. 2.81 mm) and sagittal (12.25 mm vs. 5.43 mm) prostatic urethral measurements in comparison to MRI findings for those with no prostate midline tracer uptake on PSMA PET imaging.
Here one can see PSMA PET/CT imaging that suggests a possible midline lesion and a subsequent MRI finding of urine stagnation. (Images courtesy of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.)
“Our findings suggest that PSMA uptake within the midline of the prostate is more commonly observed in patients with a prominently visible prostatic urethra at MRI, a finding that is likely associated with the stagnation of urine containing PSMA tracer,” wrote lead study author David G. Gelikman, an MRSP research scholar at the National Institutes of Health in Bethesda, Md., and colleagues.
The researchers emphasized that clinicians may misread PSMA activity within the prostatic urethra as intraprostatic lesions. Accordingly, they recommended subsequent assessment with MRI.
“PSMA uptake in the prostatic midline is often linked with urine stagnation in the prostatic urethra and can lead to misinterpretation on PSMA PET/CT,” noted Gelikman and colleagues. “Using post-void MRIs may help reduce false positives.”
Reference
1. Gelikman DG, Gonzalez EM, Lindenberg L, et al. Effect of urinary stagnation in the prostatic urethra on generating false-positive midline lesions on 18F-DCFPyL PSMA PET/CT. Poster presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU, San Francisco, Calif. Poster available at https://conferences.asco.org/gu/abstracts . Accessed January 26, 2024.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
